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A B S T R A C T
The study review guidelines on isolation of patients with tuberculosis, TB, from the World Health
Organization, WHO, Centers for Disease Control and Prevention, CDC, and the European Center for
Disease Control, ECDC. The review found that unequivocal guidelines for removing patients out of
negative-pressure isolation and de-isolation patients from either single rooms or isolation at home is
needed. Studies show that the time of effective treatment is the key parameter to follow to determine if
patients are contagious to others or not. This means that standard treatment of multi-drug resistant,
MDR, TB will not result in the patient being non-infectious. Thus it is important right from the time of
diagnosis to know if the patient is infected with MDR TB or not. Thus the early use of molecular
techniques to reveal drug susceptibility is important. Clear guidelines stating if patient with microscopy
negative sputum no matter infected with fully susceptible or MDR TB, no matter HIV positive or not is
needed.
© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis is now the commonest cause of death worldwide
from an infectious disease.1 Patients with sputum culture positive
active pulmonary tuberculosis (TB) pose a risk of transmission to
contacts both within- and outside of hospital. Multi-drug resistantciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Detection thresholds (bacteria per ml) for different diagnostic methods.42
Microscopy
Ziehl-Neelsen 104-105 AFB/ml43
Rhodamine 5-10.000 AFB/ml44
PCR
GeneXpert 100-130 CFU/ml45
Others 100-1000 CFU/ml46
Culture
Löwenstein-Jensen (10)-100 bacilli/ml47
Fluid Media (Bactec a.o.) 10-(100) bacilli/ml42
Whole genome sequencing is fast becoming a standard method for genotypic
resistance testing.48,49
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major global health challenges.2 Currently, the infectiousness of
patients with active TB is considered to be directly related to the
number of aerosol droplets carrying Mycobacterium tuberculosis
(M.tb) bacilli being propelled into the air.
Aerosol infection prevention and control procedures are
important for reducing the risk of M.tb transmission in healthcare
facilities and protection of healthcare workers, family and other
patient contacts. Contact tracing and molecular genotypic
susceptibility testing are important tools to ensure rapid identiﬁ-
cation, optimal treatment and adequate infection control measures
to be instituted.
When a pulmonary TB diagnosis is considered patients should
be isolated, preferably in a negative pressure room, until the
diagnostic workup is complete. However, negative-pressure
isolation rooms are not available in resource-limited settings
and are a limited resource even in industrialized countries. In
addition, being kept in isolation is psychologically stressful to
patients and potentially hazardous to their health because of social
isolation, poorer access to routine observation and less rigorous
physical examination. It is therefore important that patients
should be taken out of respiratory isolation once pulmonary
tuberculosis has been ruled out, or discharged home as soon as the
risk of transmission is reduced to very low levels and adequate
treatment supervision measures are in place. Prolonged isolation
of TB patients, especially those with MDR-TB or XDR-TB, is
unnecessary once appropriate treatment has been initiated.
As part of the diagnostic work-up for susceptible TB, it is well
established that isolation can be discontinued on the basis of a
single negative spot PCR of sputum, (REF) but it is less clear on
which basis isolation upon proven drug-resistant TB can be
discontinued.50
For the majority of TB patients, infectiousness declines rapidly
after commencement of appropriate TB treatment.3,4 Early
diagnosis and rapid initiation of optimal treatment, also for cases
with drug resistant TB, is essential to minimize the transmission
risk. Although the rate of decline in infectiousness varies from
patient to patient, those established on effective treatment
experience rapid declines (within days) in bacterial load and
infectiousness. The most problematic cases are those with
undiagnosed drug resistant TB who may remain infectious for
months, since they respond poorly to standard ﬁrst line treatment
and may amplify resistance during the period of sub-optimal
treatment. Current infection control recommendations are to
ideally contain the patient in a negative pressure room, until the
risk of transmission is low or negligible. However determining this
is difﬁcult in practice, and clear guidance is required to improve
and standardize management practices.
The balance that should be struck needs to consider potential
patient harms and health care costs from unnecessary isolation,
while ensuring the safety of health care staff and the wider
community. Careful consideration of this balance is of fundamental
importance for rational utilization of the limited number of
isolation rooms available. Discharge from isolation (de-isolation)
sends a signal that the transmission risk to staff, family and
members of the public is sufﬁciently low that respiratory
containment is no longer required.
In this viewpoint we review isolation and infection control
guidelines from the World Health Organization (WHO), the Centers
for Disease Control and Prevention (CDC) and the European Center
for Disease Control and Prevention (ECDC).
Methods
The WHO, CDC and ECDC websites were searched using the
search terms “tuberculosis, MDR-TB, isolation, infection control”,and the identiﬁed guidelines were evaluated by the authors
speciﬁcally looking for recommendation for de-isolation criteria
after initiation of treatment.
Results
The detection threshold of microscopy, PCR and culture are
shown in Table 1. This explains why there may be discordant
results between methods and provides the background data to
understand the methods in relation to infectiveness.
WHO guidelines
The World Health Organization (WHO) treatment guidelines for
drug-resistant tuberculosis 2016 contain no speciﬁc recommen-
dations on isolation and hospital infection control.5 It builds on the
2014 guidelines,6 which states that “Smear positive TB patients
should:
– spend as much time as possible outdoors;  sleep alone in a
separate, adequately ventilated room; and if possible;  spend as
little time as possible in congregate settings or in public
transport”, which all indicate that a “Smear positive” (Acid Fast
Bacteria, AFB, microscopy positive) patient does not necessarily
need isolation in negative pressure rooms in a hospital. The
guideline states “Culture positive extensively drug-resistant TB
(XDR-TB) patients should be in respiratory isolation at all times”,
which implies that even patients who are AFB-microscopy
negative and PCR-negative but culture positive should be kept
in isolation but not necessarily in a negative pressure room in
hospital. This applies only to XDR patients, and isolation may be
in the patient’s own home provided he/she is kept in their own
rooms and all contacts use N95 respirators when in contact with
the patient.5
The WHO policy package for infection control includes
managerial activities, administrative controls and environmental
controls.7 Managerial activities include implementation of
infection control coordination bodies at hospital level and
different activities including heath facilities construction and
renovation.7
The administrative controls are aimed at regulating the ﬂow of
staff, visitors and patients through triage, separation of infectious
cases and minimisation of the time spent at the health facility,
while maximising prevention of transmission and minimising
risks.
The environmental measures aim at enhancing ventilation
(natural or mechanical) and investing in facility improvement,
while applying strict personal protection measures including
respirators for health staff (and visitors) and surgical masks for
patients.8,9
The combination of different infection control strategies,
including diagnosis of HIV infection and treatment with antiretro-
viral therapy, are able to avert a signiﬁcant proportion of infections
and, consequently, future cases.10–12
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Patients with TB disease can be sent home even if they do not
have three negative sputum smears, provided that the patient is on
standard TB treatment, and DOT has been arranged.13 However, the
CDC guidelines are more cautious concerning transmission from
culture-positive cases with pulmonary TB,14 referring to a study
from 1985.15 Yet, the guidelines do not directly address the risk of
infection after the start of effective treatment, and refer to studies
showing that HIV patients are more susceptible to infection than
others.16–18 The CDC state that: “for most patients, infectiousness
appears to decline rapidly after adequate and appropriate
treatment is started; however, the rate of decline varies from
patient to patient”. This is not helpful for the clinician managing a
speciﬁc patient,19 and the CDC guidelines can be interpreted to
imply that the patient should remain isolated in a negative
pressure room until sputum culture is negative. Given that a
negative culture for M.tub. is usually not released as negative
earlier than after 6 to 8 weeks, such practice will keep patients in
hospitals for months.
ECDC guidelines
The European Centre for Disease Prevention and Control (ECDC)
and the European Respiratory Society (ERS) jointly developed the
European Union Standards for Tuberculosis Care (ESTC) in 2011.
These are based on The International Standards for TB Care (ISTC)
developed by WHO, but are tailored speciﬁcally to the EU setting as
global standards may not always adapt to EU settings and practices.
Also, the majority of EU countries have the resources and capacity
to implement higher standards for TB care.20
With regards to the decision on patient isolation, the EU
standards state that TB patients should ideally be isolated until
they achieve bacteriological conversion analogous to negative-
sputum microscopy. The standards speciﬁy nothing further on
isolation for drug-resistant tuberculosis, for which reason one
must assume that a negative-sputum microscopy50 applies for all
cases of pulmonary TB regardless of the susceptibility pattern of
the pathogenic tubercle bacilli.20
Discussion
When assessing the need for isolation it is key to understand
that “the rapid impact of effective chemotherapy on TB transmis-
sion, including drug-resistant strains, is the other critical
information needed to reprioritize TB transmission control efforts.
The impact of effective treatment on TB transmission is extremely
rapid and profound, including that for MDR-TB. But transmission is
on going if an ineffective regimen is used, for example when a ﬁrst-
line regimen is used in a case of MDR-TB or a MDR-TB regimen is
used in a case of XDR-TB”.5,21
The use of the Guinea-pig model where guinea pigs are kept
with the TB patient is a widely accepted model for assessing
transmission from patients with pulmonary TB. The study by
Dharmadhikari AS et al. clearly demonstrates that patients on
effective treatment rapidly lose infectivity even if they are AFB-
microscopy and culture positive.21
Multidrug-resistant tuberculosis (MDR-TB) has been suspected
of being infectious for a longer period than drug-susceptible TB,
and this concern is a key feature behind most recommendations.
The uncertainty about transmission hazard may keep patients in
isolation for months while waiting for smear or culture conversion,
but it is not well documented that a well-treated MDR-TB patient
remains infective for a longer time period. The study by
Dharmadhikari, A. S. et al. supports the EU isolation standardswith their ﬁndings on the infectiousness of MDR-TB.21 Based on
transmission studies with guinea pigs they have found that on
effective treatment, MDR-TB patients rapidly are rendered non-
infectious.
This points toward the discordance of sputum smear and
culture status and infectiousness of patients on therapy. It
encourages that effective treatment is the dominant factor
determining transmission. Mechanisms explaining the discor-
dance may include the fact that organisms in culture do not
undergo the stresses of aerosolization, drug exposure as well as
innate and adaptive host defences. Instead, growth is supported to
ensure optimal culture conditions. On the other hand, tubercle
bacilli may be capable of undergoing massive transcriptional
responses to moderate stresses, which could impact virulence or
tolerance to aerosolization. This underlines that even though
tuberculosis may be less infectious than so far feared caution
should always be taken. Furthermore, treatment of XDR-TB is often
ineffective in rapidly interrupting transmission making it infec-
tious longer than theoretically necessary.21
The study also points out that it cannot be assumed that
patients are infectious just because they are TB culture positive.
The study conﬁrms that the old “2-week-rule” correlates with a
minimal transmission risk, provided that effective and fully
adherent treatment can be guaranteed,6,22 even though most
patients on effective treatment will still be AFB-microscopy and
culture positive by two weeks.23 Persistent concerns, propagated
by previous literature stating that patients remain infectious as
long as they are sputum smear or culture positive justifying
continued isolation,24,25 seems to be unfounded.26 The key to
optimal infection control is rapid genotypic resistance testing to
identify likely drug resistance at the earliest time point possible
and to ensure that an effective treatment regimen is commenced
from the very beginning.27–29
Isolation and infection control isolation confer hardship and
anxieties for patients, healthcare workers and family members and
may further perpetuate stigmatization of MDR-TB. In addition one
must weigh the safety of the public and the patient’s community
contacts versus the morale and well being of the patient and the
available resources required to isolate the patient beyond the
recommended time frame.
A European study found pitfalls at European MDR-TB reference
centres infection control level.30,31 Although health care workers
were sufﬁciently protected in the majority of cases (199/200,
99.5%) and respirators were always available (200/200, 100%), 20%
of the cases (40/200) were not educated on cough etiquette and
other important infection control practices, and no negative
pressure rooms were available.31 Furthermore, respirator ﬁt
testing was never performed, although infection control commit-
tees were generally in place.30,31 According to European recom-
mendations, sufﬁcient respiratory isolation rooms for all new
patients admitted (at least till the exact resistance pattern is
identiﬁed and/or the patient is rendered non-infectious) and
adequate isolation procedures need to be available in centres
diagnosing and treating TB.32,33
However, much can be learned from South Africa on the
programmatic implementation of infection control principles to
manage MDR-TB.34
A combination of strict infection control measures both at
hospital level (no admission without proper infection control) and
at the patient’s home reduced the cases of MDR and XDR-TB in
Tugela Ferry between 2005 and 2015.34–36
South Africa shifted from recruiting hospital nurses and doctors
to recruiting mobile team nurses and investing in vehicles to allow
systematic home care both preparing the patient’s family before
discharge and following the patient at home after hospital
discharge.
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responsible staff at both facility and public health level. Health care
workers underwent surveillance and adequate training.5
TB risk assessment, optimised case-ﬁnding and triage were
systematically implemented at out-patient level.
Environmental measures focused on enhancing natural venti-
lation and investing in facility improvement, while applying strict
personal protection measures.
The combination of different infection control strategies,
including diagnosis of HIV infection and treatment with antiretro-
viral therapy, are able to avert a signiﬁcant proportion of XDR-TB
infections and, consequently, of future cases.
The South African experience is important also for Europe
(Eastern Europe in particular), where unnecessary and longer
hospitalizations still occur, increasing transmission to patients,
visitors and staff. A comprehensive approach to infection control
needs to include a paradigm shift from in-patient to out-patient
care, as clearly recommended by WHO.37–39
These and similar experiences, available in other settings,40,41
demonstrate the need to support adequate infection control
policies both at the facility and at the public health level, as they are
able to reduce transmission, and consequently prevent future M/
XDR TB cases.
In conclusion, we propose that international guidelines provide
clear advice concerning de-isolation of patients. De-isolation
should be based on the length of effective treatment and not on
bacteriological endpoints.
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